SCM-CGH (SCM Lifescience)

N/A

Report date: 2023/01/12 15:30:01

Base Information

Drug NameSCM-CGH (SCM Lifescience)
Drug Alias Nameautologous stem cell therapy (GvHD, acute pancreatitis, liver cirrhosis, atopic dermatitis, type I diabetes)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseDermatitis, AtopicMultiple Sclerosis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesScm Lifescience Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesScm Lifescience Co Ltd
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseDermatitis, AtopicMultiple Sclerosis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A